Changes in neuroendocrine and metabolic hormones induced by atypical antipsychotics in normal-weight patients with schizophrenia

Neuroendocrinology

Volumn 85, Issue 4, 2007, Pages 249-256

  Popovic, Vera ^a,c   Doknic, Mirjana ^a   Maric, Nadja ^a   Pekic, Sandra ^a   Damjanovic, Aleksandar ^a   Miljic, Dragana ^a   Popovic, Srdjan ^a   Miljic, Natasa ^a   Djurovic, Marina ^a   Jasovic Gasic, Miroslava ^a   Dieguez, Carlos ^b   Casanueva, Felipe F ^b  

^a Belgrade University   (Serbia)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^c University Clinical Center   (Serbia)

Author keywords

Antipsychotics; Cortisol; Ghrelin; Growth hormone; Insulin; Leptin; Weight gain

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; GHRELIN; GLUCOSE; HYDROCORTISONE; INSULIN; LEPTIN; RISPERIDONE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GHRELIN BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; HORMONE ACTION; HORMONE BLOOD LEVEL; HORMONE DETERMINATION; HUMAN; HYDROCORTISONE BLOOD LEVEL; INSULIN BLOOD LEVEL; LEPTIN BLOOD LEVEL; LIPID STORAGE; MALE; METABOLISM; NEUROENDOCRINOLOGY; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SIDE EFFECT; WEIGHT GAIN;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIPSYCHOTIC AGENTS; BODY WEIGHT; CLOZAPINE; FEMALE; GLUCOSE TOLERANCE TEST; HORMONES; HUMAN GROWTH HORMONE; HUMANS; INSULIN; MALE; METABOLIC NETWORKS AND PATHWAYS; NEUROSECRETORY SYSTEMS; PEPTIDE HORMONES; RISPERIDONE; SCHIZOPHRENIA; WEIGHT GAIN;

EID: 34547150496     PISSN: 00283835     EISSN: None     Source Type: Journal    
DOI: 10.1159/000103868     Document Type: Article

References (37)

1. Casey D, Haupt D, Newcomer J, Henderson D, Sernyak M, Davidson M, Lindenmayer JP, Manoukian S, Banjeri M, Lebovitz H, Hennekens C: Anti-psychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. J Clin Psychiatry 2004;65:4-18.
2. Tarricone I, Casoria M, Ferrari B: Metabolic risk factor profile associated with use of second generation antipsychotics: a cross-sectional study in a community mental health centre. BMC Psychiatry 2006;6:1-8.
3. Wehmeier PM, Gebhardt S, Schmidtke J, Remschmidt H, Hebebrand J, Theisen FM: Clozapine: weight gain in a pair of monozygotic twins concordant for schizophrenia and mild mental retardation. Psychiatry Res 2005;133:273-276.
4. Cowley M: Hypothalamic melanocortin neurons integrate signals of energy state Euro J Pharmacol 2003;480:3-11.
5. Coll A, Challis B, Yeo G, Farooqi I, O'Rahilly S: Melanocortin receptors and energy homeostasis. Curr Opin Endocrinol Diab 2005;12:205-210.
6. Horvath T: Synaptic plasticity in energy balance regulation. Obesity 2006;14:228S-233S.
7. Kay S, Fiszbein A, Opler LA: The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-276.
8. Mathews D, Hosker J, Rudenski A, Naylor B, Treacher D, Turner R: Homeostasis model assessment: insulin resistance and beta cell function from fasting plasma glucose and insulin concentration in man. Diabetologia 1985;28:412-419.
9. Zigman J, Elmquist J: Minireview: From anorexia to obesity - the yin and yang of body weight control. Endocrinology 2003;144:3749-3756.
10. Considine R, Sinha M, Heiman M, Kriauciunas A, Stephens T, Nyce M, Ohannesian J, Marco C, McKee L, Bauer T, Caro J: Serum immunoreactive leptin concentrations in normal-weight and obese humans. N Engl J Med 1996;334:292-295.
11. Caro J, Kolaczynski J, Nyce M, Okannesian J, Opentanova I, Goldman W, Lynn R, Zhang P, Sinha M, Considine R: Decreased cerebrospinal-fluid serum/leptin ratio in obesity: a possible mechanism for leptin resistance. Lancet 1996;348:159-161.
12. Sahu A: Leptin signaling in the hypothalamus: emphasis on energy homeostasis and leptin resistance. Front Neuroendocrinol 2004;24:225-253.
13. Licinio J, Mantzoros C, Negrao A, Cizza G, Wong M, Bongiorno P, Chrousos G, Karp B, Allen C, Flier J, Gold P: Human leptin: levels are pulsatile and inversely related to pituitary-adrenal function. Nat Med 1997;3:575-579.
14. Ravussin E, Tschop M, Morales S, Bouchard C, Heiman M: Plasma ghrelin concentration and energy balance: overfeeding and negative energy balance studies in twins. J Clin Endocrinol Metab 2001;86:4547-4551.
15. Haqq A, Farooqi S, O'Rahilly S, Stadler D, Rosenfeld R, Pratt K, LaFranchi S, Purnell J: Serum ghrelin levels are inversely correlated with body mass index, age and insulin concentrations in normal children and are markedly increased in Prader-Willi. J Clin Endocrinol Metab 2003;88:174-178.
16. Himmerich H, Fulda S, Kunzel H, Pfennig A, Dzaja A, Cummings D, Pollmacher T: Ghrelin plasma levels during psychopharmacological treatment. Neuropsychobiology 2005;52:11-16.
17. Van der Lely AJ, Tschop M, Heiman M, Ghigo E: Biological physiological, pathophysiological and pharmacological aspects of ghrelin. Endocr Rev 2004;25:426-457.
18. Flanagan D, Evans M, Monsod T, Rife F, Heptulla R, Tamborlane W, Sherwin R: The influence of insulin on circulating ghrelin. Am J Physiol 2003;284:E313-E316.
19. Theisen FM, Gebhardt S, Bromel T, Otto B, Heldwein W, Heinzel-Gutenbrunner M, Krieg JC, Remschmidt H, Tschop M, Hebebrand J: A prospective study of serum ghrelin levels in patients treated with clozapine. J Neural Transm 2005;112:1411-1416.
20. Palik E, Birkas KD, Faludi G, Karadi I, Cseh K:2005 Correlation of serum ghrelin levels with body mass index and carbohydrate metabolism in patients treated with atypical antipsychotics. Diab Res Clin Pract 2005;68:S60-S64.
21. Shiiya T, Nakazato M, Mizuta M, Date Y, Mondal M, Tanaka M, Nozoe S, Hosoda H, Kangawa K, Matsukura S: Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion. J Clin Endocrinol Metab 2002;87:240-244.
22. Nakagawa E, Nagaya N, Okamura H, Enomoto M, Oya H, Ono F, Hosoda H, Kojima M, Kangawa K: Hyperglycemia suppresses the secretion of ghrelin, a novel growth-hormone-releasing peptide responses to the intravenous and oral administration of glucose. Clin Sci (Lond) 2002;103:325-328.
23. Cummings DE: Ghrelin and the short- and long-term regulation of appetite and body weight. Physiol Behav 2006;89:71-84.
24. Hosojima H, Togo T, Odawara T, Hasegawa K, Miura S, Kato Y, Kanai A, Kase A, Uchikado H, Hirayasu Y: Early effects of olanzapine on serum levels of ghrelin, adiponectin and leptin in patients with schizophrenia. Psychopharmacology 2006;20:75-79.
25. Theisen FM, Gebhardt S, Bromel T, Otto B, Heldwein W, Heinzel-Gutenbrunner M, Krieg JC, Remschmidt H, Tschop M, Hebebrand J: A prospective study of serum ghrelin levels in patients treated with clozapine. J Neural Transm 2005;112:1411-1416.
26. Zigman JM, Nakano Y, Coppari R, Balthasar N, Marcus JN, Lee CE, Jones JE, Deysher AE, Waxman AR, White RD, Williams TD, Lachey JL, Seeley RJ, Lowell BB, Elmquist JK: Mice lacking ghrelin receptors resist the development of diet-induced obesity. J Clin Invest 2005;115:3564-3572.
27. Luque R, Kineman R: Impact of obesity on the growth hormone axis: evidence for a direct inhibitory effect of hyperinsulinemia on pituitary function. Endocrinology 2006;147:2754-2763.
28. Sernyak M, Leslie D, Alarcon R: Association of diabetes mellitus with the use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 2002;159:561-566.
29. Newcomer J, Haupt D, Fucetola R: Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 2002;59:337-345.
30. Ryan M, Collins P, Thakore J: Impaired fasting glucose tolerance in first-episode, drugnaive patients with schizophrenia. Am J Psychiatry 2003;160:284-289.
31. Zhang Z, Yao Z, Liu W, Fang Q, Reynolds G: Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. Br J Psychiatry 2004;184:58-62.
32. Ader M, Kim S, Hucking K, Kabir M, Bergman RN: Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease. Diabetes 2005;54:862-871.
33. Best L, Yates A, Reynolds G: Actions of antipsychotic drugs on pancreatic beta-cell function: contrasting effects of clozapine and haloperidol. Psychopharmacology 2005;19:596-601.
34. Sowell M, Mukhopadhyay N, Cavazzoni P, Carlson C, Mudaliar S, Chinnapongse S, Ray A, Davis T, Breier A, Henry R, Dananberg J: Evaluation of insulin sensitivity in healthy volunteers treated with olanzapine, risperidone or placebo: a prospective, randomized study using the two-step hyperglycaemic, euglycemic clamp. J Clin Endocrinol Metab 2003;88:5875-5880.
35. Tandon R, Halbreich U: The second generation 'atypical' antipsychotics: similar improved efficacy but different neuroend crineside effects. Psychoneuroendocrinology 2003;28:1-7.
36. Peters A, Schweiger U, Pellerin L, Hubold C, Oltmanns KM, Conrad M, Schultes B, Born J, Fehm HL: The selfish brain: competition for energy resources. Neurosci Biobehav Rev 2004;28:143-180.
37. Peters A, Pellerin L, Dallman M, Oltmans K, Schmiger U, Born J, Fehm J: Causes of obesity: looking beyond the hypothalamus. Prog Neurobiol 2007;81:61-88.